Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as a tablet for oral use. It treats chronic lymphocytic leukemia, Hodgkin's lymphoma, non‑Hodgkin lymphoma and other lymphoid malignancies in adult patients. GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leukeran is an oral alkylating antineoplastic indicated for several lymphoid cancers. - Chronic lymphocytic leukemia: helps control disease progression and prolongs survival. - Hodgkin's lymphoma: contributes to remission when used as part of combination chemotherapy. - Non‑Hodgkin lymphoma: reduces tumor burden and extends progression‑free intervals.

Leukeran may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Bone marrow suppression: decreased white blood cells, red cells, or platelets. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Diarrhea: mild to moderate loose stools.

Serious or Rare Side Effects: - Severe myelosuppression: risk of life‑threatening infections or bleeding. - Secondary malignancies: potential development of new cancers. - Pulmonary fibrosis: progressive lung scarring. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or liver injury.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity. - Monitor blood counts: perform regular complete blood count testing. - Assess renal function: adjust use in patients with impaired kidney function. - Evaluate hepatic function: check liver enzymes periodically. - Avoid use in pregnancy: drug is contraindicated due to fetal risk. - Use effective contraception: both male and female patients of reproductive potential should employ reliable birth control. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Chlorambucil can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection. - Other myelotoxic agents (e.g., cyclophosphamide, azathioprine): increase risk of severe bone‑marrow suppression. - High‑dose radiation therapy: amplifies tissue toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Anticoagulants (warfarin, DOACs): heightened bleeding tendency. - Allopurinol: potential enhancement of myelosuppression.